Clodronate and osteoporosis

Maturitas

Volumn 23, Issue SUPPL., 1996, Pages

  Kanis, J A ^a   McCloskey, E V ^a   Beneton, M N C ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bisphosphonates; Clodronate; Osteoporosis

Indexed keywords

ALENDRONIC ACID; CLODRONIC ACID; ETIDRONIC ACID; PAMIDRONIC ACID; TILUDRONIC ACID;

AGED; AGING; DISEASE ASSOCIATION; FEVER; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; MENOPAUSE; MINERALIZATION; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PROSPECTIVE STUDY; REVIEW; THROMBOPHLEBITIS;

EID: 0029742163     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5122(96)01018-3     Document Type: Article

References (26)

1. Fleisch H. Bisphosphonates: history and experimental basis. Bone 1987; 8 (Suppl.): 523-528.
2. Kanis JA. Pathophysiology and treatment of Paget's disease of bone. Martin Dunitz: London, 1991.
3. Kanis JA, McCloskey EV. The use of clodronate in disorders of calcium and skeletal metabolism. Prog Basic Clin Pharmacol 1990; 4: 89-136.
4. Kanis JA, O'Rourke N, McCloskey EV. Consequences of neoplasia induced bone resorption and the use of clodronate. Int J Oncol 1994; 5: 713-731.
5. Elomaa I, Blomqvist C, Porkka L, Lamberg-Allardt C, Borgstrom GH. Treatment of skeletal disease in breast cancer. A controlled clodronate trial. Bone 1987; 8 (Suppl.): 53-56.
6. 2MDP) on skeletal lesions in multiple myeloma. Metab Bone Dis Rel Res 1982; 4:163-168.
7. Paterson AHG, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Oral clodronate decreases skeletal morbidity in patients with bone metastases for breast cancer. A double blind controlled trial. J Clin Oncol 1993; 11: 59-65.
8. Parfitt AM. The physiologic and clinical significance of bone histomorphometric data. Bone histomorphometry: techniques and interpretation. In: Recker R, ed. pp. 143-223. Boca Raton, Florida: CRC Press, 1982.
9. Kanis JA. Osteoporosis. Blackwell Science Publishers, Oxford, 1995.
10. Kanis JA. Treatment of osteoporotic fracture. Lancet 1984; i: 27-33.
11. Plosker GL, Goa KL. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 1994; 47: 945-982.
12. Filipponi P, Pedetti M, Fedeli L et al. Clodronate is effective in preventing postmenopausal bone loss: A comparative study with transdermal hormone replacement therapy. J Bone Miner Res 1995; 10: 697-703.
13. Chesnut CH. Synthetic calcitonin, diphosphonates and anabolic steroids in the treatment of postmenopausal osteoporosis. Osteoporosis 1984, In: Christiansen C, Arnaud CD, Nordin BEC, Parfitt AM, Peck WA, Riggs BL, eds. pp. 549-55. Copenhagen: Glostrup Hospital, 1984.
14. Giannini S, D'Angelo A, Malvasi L, Castrignano R, Tronca R, Nobile M, Crepaldi G. Effects of one-year cyclical treatment with clodronate on bone mass and mineral metabolism in postmenopausal osteoporosis. Bone 1993; 14: 137-141.
15. McCloskey EV, Beneton MNC, O'Rourke N, Eyres K, O'Doherty D, Kanis JA. The effect of phosphate and in-termittent clodronate in post-menopausal osteoporosis. Osteoporosis 1990. In: Christiansen C, Overgaard K, eds. pp. 1401-1402, Osteopress ApS: Copenhagen, 1990.
16. Lepore L, Pennesi M, Barbi E, Pozzi R. Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate. Clin Exp Rheumatol 1991; 9 (Suppl. 6): 33-35.
17. Filipponi P, Cristalini S, Pedetti M, Boldnni S, Massoni C, Rizzelo E, Policani G, Fedeli L. Clodronate and osteoporotic vertebral fracture rate. Effect of a five-years cyclical therapy. Bone 1995; 16 (Suppl.): 1605.
18. Yates AJP, Jones TH, Mundy KI, Hague RV, Brown CB, Guilland-Cumming D, Kanis JA. Immobilisation hypercalcaemia in adults and treatment with clodronate. Br Med J 1984; 289: 1111-1112.
19. Minaire P, Berard E, Meunier PJ, Edouard C, Goedert G, Pilonchery G. Effects of disodium dichloromethylene diphosphonate on bone loss in paraplegic patients. J Clin Invest 1981; 68: 1086-1092.
20. Minaire P, Depassio J, Berard E, Meunier PJ, Edouard C, Pilonchery G, Goedert G. Effects of clodronate on immobilisation bone loss. Bone 1987; 8 (Suppl.): 63-68.
21. Elomaa I, Blomqvist C, Porkka L, Holmstrom T. Experiences of clodronate in treatment of multifocal eosinophilic granuloma of bone. J Intern Med 1989; 225: 59-61.
22. Cundy T, Beneton MNC, Darby M, Marshall WJ, Kanis JA. Osteopenia in systemic mastocytosis: natural history and responses to treatment with inhibitors of bone resorption. Bone 1987; 8: 149-155.
23. Steiniche T, Hasling C, Thamsborg G, Storm T, Sorensen OH, Mosekilde L, Melsen F. A histomorphometric analysis of iliac crest bone biopsies from patients treated with intermittent cyclical etidronate therapy for postmenopausal osteoporosis. Osteoporosis 1977. Christiansen C, Johansen JS, Riis BJ, eds. pp. 182-1187. Osteopress ApS: Copenhagen, 1977.
24. McCloskey EV, Yates AJP, Beneton MNC, Galloway J, Harris S, Kanis JA. Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone 1987; 8 (Suppl.): 35-41.
25. Watts NB, Harris ST, Genant HK, Wasnich R, Miller PD. Intermittent cyclical etidronate treatment in postmenopausal osteoporosis. N Engl J Med 1990; 323: 73-79.
26. Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OHN. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990; 322: 1265-1271.